On July 1, Georgia became the first US state to introduce a Medicaidpreferred drug list for which products are selected based on their clinical merits and prevailing prescribing patterns, rather than simply cost, according to Reuters reports.
Under the new scheme, co-pays charged to Medicaid recipients start at 50 cents for a preferred drug, rising as high as $3 for non-preferred drugs. However, as Centers for Medicare and Medicaid regulations currently permit states to charge up to $3 per prescription for enrollees in these programs, implementation of the new scheme by Georgia's Department of Community Health has required neither new legislation nor a federal waiver.
At the same time as introducing the preferred list, the state has newly implemented a tiered drug benefit for its employees, for whom prescription co-pays now start at $10 for a generic, rising to $20 for preferred products and higher charges for non-preferred products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze